Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of FluBlok in Healthy Children
NCT00336453Phase 2Completed
- Sponsor
- Protein Sciences
- Start
- Oct 2006
- Primary completion
- Jul 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of influenza vaccine, recombinant hemagglutinin in influenza (5 arms), sponsored by Protein Sciences. Primary endpoint: Evaluation of safety and reactogenicity. Started Oct 2006; status: completed.
02
Drugs
influenza vaccine, recombinant hemagglutinin
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00336453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00336453.